1887

oa SA Pharmaceutical Journal - A review of metformin and its place in the diabetes guidelines : review

 

Abstract

Metformin is considered to be the initial drug of choice for type 2 diabetes mellitus, particularly in overweight patients. This is based on its effectiveness in achieving glycaemic control, its favourable effects on weight, its low risk of causing hypoglycaemia and its reasonable cost. More importantly, metformin has also been consistently shown to have a favourable effect on cardiovascular risk factors, and to improve cardiovascular outcomes. It can be combined with other oral hypoglycaemic agents, as well as insulin, allowing for a beneficial additive effect.


This article provides a brief overview on the use of metformin, as recommended by the Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA), in its 2012 guidelines for the management of type 2 diabetes.

Loading

Article metrics loading...

/content/mp_sapj/80/10/EJC146888
2013-11-01
2016-12-08
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error